详情页 - 昆明医科大学第一附属医院知识库

当前位置：首页 > 详情页

PGAM4 silencing inhibited glycolysis and chemoresistance to temozolomide in glioma cells

108| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Neurosurgery, Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, China. [2]Department of Neurosurgery, The First Affiliated Hospital of Kunming Medical University, Kunming, China. [3]Department of orthopedics, Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, China.

出处：

DOI：

ISSN：

关键词： brain tumor chemoresistance glioma glycolysis phosphoglycerate mutase 4 (PGAM4)

摘要：

Gliomas account for about 80% of malignant brain tumors. The incidence of a new brain tumor is 6.4 per 100,000 persons per year with an overall 5-year survival rate of 33.4%. Regardless of the great advances that have been made in recent years, the causes and pathogenesis of glioma remain unclear. Here we study how phosphoglycerate mutase 4 (PGAM4) contributes to glioma. Using a variety of methods to examine glioma cell viability, proliferation, apoptosis, glycolysis, as well as ChIP coanalysis with modified histone H3, we showed that PGAM4 was significantly upregulated in patients with glioma and associated with poor survival. Silencing PGAM4 attenuated cell viability, proliferation, and glycolysis in T98G cells and suppressed tumor growth in vivo, while overexpressing PGAM4 promoted cell viability, proliferation, and glycolysis in U251 cells via regulating glycolysis pathway. Study also revealed that PGAM4 was regulated by EP300-mediated modifications of H3K27ac. PGAM4 silencing inhibited cell viability and proliferation, suppressed tumor growth, and decreased chemoresistance to temozolomide in glioma cells through suppressing glycolysis.© 2022 International Federation for Cell Biology.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 3 区生物学

小类 | 4 区细胞生物学

JCR分区：

出版当年[2023]版：

Q3 CELL BIOLOGY

最新[2023]版：

Q3 CELL BIOLOGY

影响因子： 3.3 最新[2023版] 3.6 最新五年平均 3.3 出版当年[2023版] 3.6 出版当年五年平均 3.9 出版前一年[2022版]

第一作者：

第一作者机构： [1]Department of Neurosurgery, Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, China.

通讯作者：

通讯机构： [1]Department of Neurosurgery, Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, China. [3]Department of orthopedics, Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, China. [*1]Department of orthopedics, Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, No.1558, Sanhuan North Rd, Wuxing District, Huzhou 313000, China. [*2]Department of Neurosurgery, Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Kunming 650032, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]CCL2 activates AKT signaling to promote glycolysis and chemoresistance in glioma cells. [2]DWI在脑转移瘤和恶性胶质瘤鉴别诊断中的价值 [3]应用U251胶质瘤细胞、脑内皮细胞和周细胞体外构建血瘤／脑屏障模型的研究 [4]胶质瘤细胞及其干细胞的放疗敏感性差异 [5]脑肿瘤干细胞的研究进展 [6]National Brain Tumour Registry of China (NBTRC) statistical report of primary brain tumours diagnosed in China in years 2019-2020 [7]NOD2 reduces the chemoresistance of melanoma by inhibiting the TYMS/PLK1 signaling axis [8]Reduced glycolysis contributed to inhibition of testis spermatogenesis in rats after chronic methamphetamine exposure [9]视神经胶质细胞瘤误诊为颅咽管瘤一例 [10]miR-142-3p Modulates Cell Invasion and Migration via PKM2-Mediated Aerobic Glycolysis in Colorectal Cancer